Delta4 will be represented at #Bio€quity Europe in Prague by Josef Thalmann, who will be on-site for investor meetings and collaboration discussions in the field of data-driven drug repositioning and indication expansion. If you plan to attend, feel free to reach out and schedule a conversation!

WORLD #LIVER DAY: Liver safety and liver disease aren’t separate problems.
Cases like #Ontozry show risks still emerge post-approval, while PBC/PSC reflect immune-driven damage.
Different triggers—same system under stress.

Read more on #Delta4's work in #PBC/#PSC: delta4.ai/development-...

In proof-of-concept clinical trials, mechanism matters more than magnitude. Targeted #biomarkers and multi-#omics approaches help researchers to:
🧬Confirm #target engagement, 🧬Identify #responder subgroups, 🧬Reduce noise in small #cohorts.
Read more:
delta4.ai/proof-of-con...

💡 #Collagen fragments in urine can predict #mortality across ICU and non-ICU populations (#Proteomics).
Not a single biomarker, but a systemic readout of #tissue integrity and structural change.
Read more on this non-invasive signal in the following study: doi.org/10.1002/pmic...
#BiomarkerResearch

At Delta4, our commitment to the rare disease community is grounded in both compassion and rigorous data science. Together, we are transforming awareness into meaningful action—supporting innovation and hope for everyone affected by rare diseases. 💙💪

#Delta4 #RareDisease #Innovation

Better health won’t come from fitting patients into models, but from understanding when they don’t fit. AI is great at finding patterns — but biology doesn’t always follow them.
Rare diseases, individual variability, and context need smarter approaches.

#WorldHealthDay #TogetherForScience

💡 Most drug discovery tools look at biology in segments. Hyper-C is built to see diseases and drugs play out across systems. Explore Hyper-C's core components at 📍 delta4.ai/hyper-c
#DrugDiscovery #SystemsBiology #Biotech #TargetDiscovery #BiomarkerID #indicationExpansion

Great discussions at the #PICKED webseminars 👏
9 DC presentations, strong supervisor feedback, and real cross-project exchange.

More: www.projectpicked.eu/news-and-eve...

Next up: Tallinn (15–16 Sept)

#HorizonEU #MSCA #RareDiseases

#PerMediK’s 8th Meeting marked the start of its final year. A strong network driving collaboration in personalised medicine for #CKD — now facing the key task of aligning scientific exchange with real-world impact. Great to have Paul & Kinga from Delta4 on site, exchanging ideas and experience.

💡What if the next #KidneyDisease therapy is already in your pipeline? By leveraging in-silico modeling and network biology, we can:
✔ Identify new targets ✔ Reveal biomarkers ✔ Expand indications for existing assets ✔ De-risk development early.
Let's rethink kidney disease as an #opportunity.

Kidney disease highlights both the promise and the challenge of PoC clinical trials.
Slow disease progression and heterogeneous biology make traditional endpoints impractical in early studies.
🧬Explore more: delta4.ai/proof-of-con...

🌍 #Kidney disease often starts quietly — sometimes with small, seemingly unrelated changes in routine lab results. We believe that understanding connections across pathways and systems is key to uncovering new therapeutic strategies. Let's look beyond individual data points & find new approaches.

🪢Seeing connections changes decisions. Our new Services page features an interactive map of Delta4’s expertise. Connecting the dots is our specialty. Now you can explore the many dimensions of drug and biomarker discovery at your own pace. 💡Learn more: delta4.ai/services #Delta4 #DrugDiscovery

On today's International Women's Day, we celebrate the #women shaping #science, and the progress still lying ahead. 💡Biological sex differences profoundly affect disease mechanisms, drug metabolism, and treatment response. Closing these gaps is essential for safer and more effective therapies.

💡 Endometriosis is not just a local disease & is increasingly understood as a systemic, neuroimmunological condition. During Endometriosis Awareness Month, we invite partners to explore new, systems-level approaches — from biomarker identification to therapeutic hypotheses. Let’s connect! #EndoMarch

Rare Disease Day reminds us that behind every statistic is a story of resilience. Delta4 is committed to advancing data‑driven solutions that support clearer understanding and stronger outcomes for the rare disease community. 💙💪

#Delta4 #RareDiseaseDay #RareDiseases

Common challenges in proof of concept (PoC) studies:
🧬Patient heterogeneity 🧬Small sample sizes & weak signal detection 🧬Biomarkers that don’t align with drug mechanisms
Learn how we tackle these 👇
delta4.ai/proof-of-con...

Ever wondered how Hyper-C works and what real-world impact it delivers? A new overview on our website features four success stories that highlight the strength of our “dream team”: systems biology, computational modeling, and deep biological expertise.
Explore more: delta4.ai/success-stor...

PoC clinical trials are one of the most critical inflection points in drug development, answering the question:
Does the drug work in humans the way it was intended to? When done poorly, PoC trials can prematurely eliminate promising therapies.
👉https://delta4.ai/proof-of-concept-clinical-trials/

At Delta4 we’re always looking for key partnerships that are mutually beneficial. Together, we can #accelerate progress and accomplish more 🤝

Connect with us to explore #collaboration opportunities!
delta4.ai/partnering/

#Delta4

Discover the EMA’s 2025 highlights, including key repurposed and expanded medicines like Fabhalta, Mounjaro and Uplizna.

Dive into the full overview: www.linkedin.com/posts/europe...

#Delta4 #EMA

2025 was a landmark year for #semaglutide.
Starting as a #diabetes and weight-management therapy, it has now expanded into kidney, liver, and cardiovascular disease — reflecting a broader shift toward mechanism-driven treatment strategies and showing the importance of indication expansion. #ozempic

📄 Submissions are open via the KI author system.
🔗 lnkd.in/ebhJ5m86

Kidney International® introduces “Clinical Journey in Translational Medicine,” putting patient journeys at the center of translational research. A timely reminder that real progress happens when patient experience, clinical insight, and disease mechanisms move together.

~80% of Autoimmune Patients are Female 🧬 Yet, female biology has long been underrepresented in research. 🔬 On Women’s Health Research Day, we highlight the need for inclusive, evidence-based science. #WomensHealthResearchDay #AutoimmuneDisease #Endometriosis #Sjögrens

Many Long COVID patients meet ME/CFS criteria but face care gaps: few treatment centers and delayed action plans. Computational biology offers hope, helping to guide faster, targeted treatment paths.
Read more: delta4.ai/long-covid/

Back in 2023, Delta4 published OntoloViz in Bioinformatics Advances: a GUI for visualizing drugs & diseases using MeSH & ATC ontologies. As datasets grow, ontology-based interactive visualization tools like this are more relevant than ever for drug repositioning & phenotype exploration.

💊 In 10 years, #pharmacists won’t just dispense — they’ll interpret patient data, guide personalized medicine, advise on repurposed drugs, and use AI as a co-pilot. Same white coat, very different role: trusted interpreters of data, evidence, and patient individuality. #NationalPharmacistDay

🧬 #ADPKD is the most common genetic kidney disease—often leading to kidney failure, dialysis, or transplantation.
Delta4 partners with the MedUni Innsbruck, modeling disease pathways, screening compounds & testing biomarkers. Our ADPKD Drug Discovery Project is designed to improve treatments.

✨Looking ahead to 2026: Delta4 aims to grow organically and support more pharma teams in finding new targets, new indications, and repurposing opportunities for their assets. Let’s connect!